Ansamycin antibiotic compound that inhibits Hsp90 activity (IC50
= 2 μ
M) by binding to the ATP-binding site. Exhibits antitumor and cytocidal activities (IC50
~ 0.4 μ
M) by causing degradation of key oncogenic client proteins such as ErbB2 and cRaf1. Displays higher affinity and potency than geldanamycin
(Cat. No. 1368).
Soluble in DMSO
Desiccate at -20°C
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
Antitumor and cytocidal activities of a newly isolated benzenoid ansamycin, macbecin I.
Ono et al.
Natural product origins of Hsp90 inhibitors.
Uehara et al.
Curr.Cancer Drug Targets, 2003;3:325
Molecular characterization of macbecin as an Hsp90 inhibitor.
Martin et al.